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Abstract
Objectives The aims of the study were to evaluate usage
rates of warfarin in stroke prophylaxis and the association
with assessed stages of stroke and bleeding risk in long-
term care (LTC) residents with atrial fibrillation (AFib).
Methods A cross-sectional analysis of two LTC databases
(the National Nursing Home Survey [NNHS] 2004 and an
integrated LTC database: AnalytiCare) was conducted. The
study involved LTC facilities across the USA (NNHS) and
within 19 states (AnalytiCare). It included LTC residents
diagnosed with AFib (International Classification of Dis-
eases, Ninth Revision, Clinical Modification [ICD-9-CM]
diagnostic code 427.3X). Consensus guideline algorithms
were used to classify residents by stroke risk categories:
low (none or 1? weak stroke risk factors), moderate
(1 moderate), high (2? moderate or 1? high). Residents
were also classified by number of risk factors for bleeding
(0–1, 2, 3, 4?). Current use of warfarin was assessed. A
logistic regression model predicted odds of warfarin use
associated with the stroke and bleeding risk categories.
Results The NNHS and AnalytiCare databases had 1,454
and 3,757 residents with AFib, respectively. In all, 34 %
and 45 % of residents with AFib in each respective
database were receiving warfarin. Only 36 % and 45 % of
high-stroke-risk residents were receiving warfarin, respec-
tively. In the logistic regression model for the NNHS data,
when compared with those residents having none or
1? weak stroke risk and 0–1 bleeding risk factors, the odds
of receiving warfarin increased with stroke risk (odds
ratio [OR] = 1.93, p = 0.118 [1 moderate risk factor];
OR = 3.19, p = 0.005 [2? moderate risk factors]; and
OR = 8.18, p B 0.001 [1? high risk factors]) and
decreased with bleeding risk (OR = 0.83, p = 0.366
[2 risk factors]; OR = 0.47, p B 0.001 [3 risk factors];
OR = 0.17, p B 0.001 [4? risk factors]). A similar
directional but more constrained trend was noted for the
AnalytiCare data: only 3 and 4? bleeding risk factors were
significant.
Conclusions The results from two LTC databases suggest
that residents with AFib have a high risk of stroke. War-
farin use increased with greater stroke risk and declined
with greater bleeding risk; however, only half of those
classified as appropriate warfarin candidates were receiv-
ing guideline-recommended anticoagulant prophylaxis.
1 Introduction
Atrial fibrillation (AFib), a condition that becomes more
prevalent with advancing age [1], is the most common
sustained cardiac arrhythmia [1, 2]. Lifetime risks for
developing AFib are 1 in 4 for men and women C40 years
of age [3]. AFib is a major independent risk factor for
stroke; patients with this condition have a nearly fivefold
excess in age-adjusted incidence of stroke [4].
The potential benefit of stroke risk reduction from
warfarin prophylaxis is substantial. In a meta-analysis of
clinical trials, when compared with no antithrombotic,
G. Reardon (&)  M. Neidecker
Informagenics, LLC, 450 W. Wilson Bridge Rd.,
Suite 340, Worthington, OH 43085, USA
e-mail: greardon@informagenics.com
G. Reardon  M. Neidecker
The Ohio State University, Columbus, OH, USA
W. W. Nelson  A. A. Patel
Janssen Scientific Affairs, LLC, Raritan, NJ, USA
T. Philpot
Profiles & Interventions, Inc., Atlanta, GA, USA
Drugs Aging (2013) 30:417–428
DOI 10.1007/s40266-013-0067-y
adjusted-dose warfarin reduced stroke in AFib by 64 % and
death by 26 %, and compared with antiplatelet therapy, it
reduced stroke in AFib by 39 % (all significant at 95 %
confidence interval (CI); a 9 % reduction in death for
warfarin vs. antiplatelets was not significant) [5]. Recent
evidence suggests that net clinical benefit (annual rate of
ischaemic strokes and systemic emboli prevented by war-
farin minus intracranial haemorrhages attributable to war-
farin, then multiplied by an impact weight) is clear among
patients having a Cardiac Failure, Hypertension, Age,
Diabetes, [and] Stroke [Doubled] [6] (CHADS2) score of
C2 [7, 8].
Prescribing guidelines for antithrombotic (anticoagulant
and antiplatelet) prophylaxis in patients with AFib were
issued by the American College of Cardiology (ACC) and
the American Heart Association (AHA) jointly with the
European Society of Cardiology (ESC) in 2006 [1], by the
ESC alone in 2010 [9], and by the American College of
Chest Physicians (ACCP) in 2008 [10] and were updated
by the ACCP in 2012 [11]. The American Medical
Directors Association (AMDA) recently released an
updated stroke management guideline that addresses, in
part, the use of anticoagulant therapy in nursing home
residents with AFib [12].
The guidelines above state that AFib patients with
moderate or high risk factors for stroke are candidates for
warfarin therapy. Although specific, listed stroke and
bleeding risk factors vary somewhat among guidelines,
ACC/AHA/ESC (2006), ACCP (2008) and ESC (2010)
recommend long-term use of aspirin in patients with no
stroke risk factors (ACCP 2012 recommends no use of
antithrombotics), aspirin or oral anticoagulation in patients
with 1 moderate risk factor (ACCP 2012 recommends oral
anticoagulation as preferred), and oral anticoagulation as
preferred in patients with 1? high risk factor(s) or 2?
moderate risk factors. The AMDA 2011 guidelines rec-
ommend using CHADS2, but do not link specific scores
with a recommendation for warfarin use.
All guidelines above recommend that oral anticoagula-
tion prophylaxis be considered on the basis of degree of
stroke risk, but also with consideration of the risk of
bleeding. In both the ACC/AHA/ESC 2006 and the ACCP
2008 guidelines, studies regarding bleeding risk and war-
farin use are discussed, but no systematic scoring algorithm
is recommended. The ESC 2010, AMDA 2011 and ACCP
2012 guidelines specifically demonstrate the use of various
algorithms for scoring bleeding risk. However, in contrast
to the evaluation of stroke risk, none of these guidelines
specifically suggests when to withhold warfarin on the
basis of a particular assessment of bleeding risk.
Previous local and regional long-term care (LTC)
studies have shown that warfarin was used in only 17–57 %
of residents with AFib [13–17]. Lau et al. [16] further
found that warfarin was often inconsistently prescribed in
LTC when considering resident risk factors for stroke and
bleeding, where many optimal candidates for warfarin
therapy received suboptimal treatment and residents at high
risk for bleeding received excessive treatment. In a recent
study, Ghaswalla et al. [18] examined the US National
Nursing Home Survey (NNHS) database and concluded
that 54 % of US residents with AFib who had indications
for, but no contraindications against, warfarin use were
prescribed neither warfarin nor antiplatelet agents, sug-
gesting underuse of antithrombotic therapy. In an earlier
study, McCormick et al. [17] found that warfarin use
increased with magnitude of overall stroke risk and
decreased with overall bleeding risk in all residents with
AFib, but that this relationship was significant only for high
bleeding risk (having 2? risk factors).
The aim of the current study was to expand the method
used by McCormick et al. [17] to quantify, by assignment
to stages of increasing severity, combined assessment of
overall bleeding risk and stroke risk among all LTC resi-
dents with AFib (i.e. without removal of subjects from the
analysis who had been screened as candidates for or against
warfarin use). In this updated approach we examined the
relationship of warfarin use with these risk stages during a
period following publication of CHADS2 and release of
formalized guidelines for assessing the risk and benefit of
warfarin for stroke prevention in AFib. At the time of the
current study, warfarin was the only prescribed oral anti-
coagulant in the USA. We assessed whether warfarin use
increases and declines, respectively, across stages of
increasing stroke and bleeding risk. We further evaluated
rates of warfarin use among stroke risk and bleeding risk




This study applied a retrospective cross-sectional analysis
of residents across multiple LTC facilities. Two databases
were analysed: the publicly available cross-sectional
NNHS database and the proprietary longitudinal Analyti-
Care database.
2.2 National Nursing Home Survey Database
The NNHS is currently administered by the US Centers for
Disease Control and Prevention (CDC; http://www.cdc.
gov/nchs/nnhs.htm). This database consists of a continuing
series of national sample surveys of nursing homes, their
residents and their staff. Eligible facilities consisted of
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those having three or more beds that are certified to provide
reimbursable services by Medicare or Medicaid or that are
licensed by an individual state. In the most recent survey
year, calendar year 2004, 1,500 facilities were randomly
drawn from 17,000 nursing homes listed in either the
Centers for Medicare and Medicaid Services file of US
nursing homes (skilled and other nursing facilities) or state
nursing home licensing lists. De-identified, public-use,
single-point-in-time data were obtained through computer-
assisted personal interviews with facility administrators
and designated staff. Interviewees used administrative
records to answer questions about the facilities, staff, ser-
vices and programmes, and used medical records to answer
questions about the residents. Data for residents were
drawn by simple random sampling in facilities that agreed
to participate.
For the current study, eligible residents included those
of the 13,507 sampled residents in the NNHS database who
had an open-ended entry for AFib (International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] diagnostic code 427.3X) in any of the 15
available current diagnosis fields on the resident ques-
tionnaire. In the most recent 2004 release, current drug
therapy was available and was used in this study. This
included all agents taken the day before the resident
questionnaire was completed or recorded as ‘regularly
scheduled’. Resident demographics, comorbid conditions,
activities of daily living (ADL) assessments, history of
falling, and specific stroke and bleeding risk assessments
were obtained from the resident data file.
2.3 AnalytiCare Long-Term Care Database
The AnalytiCare study database (http://www.analyticare.
com) was drawn from a universe of *100,000 LTC resi-
dents of *200 nursing homes in 19 states over the study
period 1 January 2007–30 June 2009. Available data
included all elements from the Minimum Data Set (MDS)
version 2.0 [19] and pharmacy dispensing records. The
MDS, which is used in the USA, Canada and more than 20
other countries, is a detailed collection of measures and
indicators (including assessments of physical and cognitive
functioning, listings of current conditions, assessment of
pain, among many others) that are completed by LTC staff
to provide a comprehensive assessment of each resident’s
functional capabilities and to identify health problems. In
the USA, the MDS is mandated to be completed for all
residents in federally certified facilities at least once
quarterly, and also upon admission, discharge or a signif-
icant change in resident health status (version 3.0 was
implemented in October 2010). Prior to their release for the
study, data were de-identified by AnalytiCare accord-
ing to Health Insurance Portability and Accountability
Act–compliant safe harbour rules and were exempt from
the requirement of review by an internal review board.
The MDS was used to identify chronic resident condi-
tions, including AFib. AFib is not one of the listed
‘checkbox’ conditions in MDS Sect. I1, but is identified in
the section permitted for open-ended entry of conditions in
Sect. I3 [19]. Eligible residents in the current study (1) had
complete pharmacy data, C2 MDS assessments, and an
entry for AFib (ICD-9-CM diagnostic code 427.3X) in any
MDS assessment completed during the study period (these
were the minimum criteria for production of the de-iden-
tified database released by AnalytiCare); (2) had an MDS
assessment at least 1 year prior to the end of the study
period (to assure adequate follow-up was not constrained
by the study database); (3) had a diagnosis for AFib within
1 year of the earliest MDS assessment; (4) had a complete
admission or annual assessment within 1 year of the ear-
liest MDS assessment (since these forms provide space for
up to five open-ended ICD-9 code entries vs. only two for
quarterly assessments); and (5) were C18 years of age on 1
January 2007 and his/her sex was known. For study resi-
dents, current drug therapy included all agents dispensed
30 days before through to 60 days after the earliest AFib
entry described in item 3 above (to establish a limited date
range to evaluate concurrent drug use with a single indexed
notation of the AFib condition). Comorbid condition data
were obtained on all MDS (checkbox) or open-ended
entries during the 1-year period starting from the earliest
MDS assessment.
2.4 Measurement of Stroke and Bleeding Risk
For the NNHS, data from the single-point-in-time survey
and, for AnalytiCare, from a summary of the 90-day drug
therapy period and the 1-year MDS assessment period
(noted above) were used to identify stroke and bleeding
risk factors for individual residents. Specific stroke risk
factors (listed in Table 1), based primarily on CHADS2 [6]
were obtained directly from AHA/ACC/ESC [1] and
ACCP [10] guidelines and were stratified by ‘high risk’ for
stroke and ‘moderate risk’ for stroke. Fuster et al. [1] also
listed some factors with ‘less validated’ or ‘weak associa-
tion’ with stroke. In the current study, residents were
assigned to one of the following stroke-risk categories: low
(none or 1? weak stroke risk factors), moderate (1 mod-
erate), high (2? moderate or 1? high).
At the time this study was designed, the AFib risk-
specific HAS-BLED (Hypertension, Abnormal renal/liver
function, Stroke, Bleeding history or predisposition, Labile
international normalized ratio, Elderly [ 65 years], Drugs/
alcohol concomitantly) [20] and atherothrombotic risk-
specific REACH (REduction of Atherothrombosis for
Continued Health) [21] bleeding algorithms had not yet
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Table 1 Assessment of stroke and bleeding risk among residents with atrial fibrillation: warfarin users and non-users
















Previous strokec [1, 10] 20 12 0.001 24 23 0.405
TIA [1, 10] 5 3 0.079 4 3 0.110
Systemic embolism [1, 10] 0 0 0.140 0 0 0.441
Mitral stenosis [1] 1 0 0.046 0 0 0.177
Prosthetic heart valve [1] 0 0 0.139 0 0 0.704
Moderate risk factors
Age C75 years [1, 10] 89 88 0.636 80 83 0.003
Hypertension [1, 10] 61 59 0.399 75 73 0.168
Congestive heart failurec [1, 10] 41 38 0.266 47 40 \0.001
Diabetes mellitus [1, 10] 24 23 0.667 38 34 0.026
Less-validated or weaker risk factors
Female sex [1] 72 69 0.344 64 63 0.273
Age 65–74 years [1] 9 8 0.675 15 12 0.002
Coronary artery disease [1] 26 25 0.694 13 12 0.346
Thyrotoxicosis [1] 5 4 0.633 0 0 0.502
Bleeding risk factors
AFFIRM study bleeding risk factors [22]d
Older agee n/a n/a n/a n/a n/a n/a
Aspirin use 11 48 \0.001 5 8 \0.001
Liver disease 0 0 0.128 0 1 0.344
Renal disease 2 4 0.056 14 14 0.750
Diabetes mellitus 24 23 0.667 38 34 0.026
Congestive heart failure 41 38 0.266 47 40 \0.001
Other bleeding risk factors
Age C65 years [23] 98 96 0.073 95 95 0.655
Previous gastrointestinal bleed [23] 2 4 0.153 2 3 0.029
Previous stroke or TIA [23] 24 14 \0.001 26 25 0.211
Dementia or cognitive impairment [24] 12 17 0.042 24 40 \0.001
Anaemia [23] 17 21 0.063 26 30 0.011
NSAID use 2 3 0.251 4 5 0.209
Antiplatelet use 11 55 \0.001 10 22 \0.001
History of falls (in last 180 days) [24] 41 37 0.225 42 44 0.249
Internal bleeding (in last 7 days) [24] n/a n/a n/a 1 1 0.492
LVEF left ventricular ejection fraction, n/a not applicable, NNHS National Nursing Home Survey, NSAID nonsteroidal anti-inflammatory drug,
TIA transient ischaemic attack
a Sampling weights were applied to NNHS data to determine population estimates and frequencies
b Chi-square test
c Fuster et al. [1] list ‘‘previous stroke,’’ whereas Singer et al. [10] list ‘‘prior ischemic stroke.’’ Data did not distinguish between ischaemic and
haemorrhagic stroke; therefore, haemorrhagic stroke is included in these percentages. Fuster et al. [1] lists ‘‘LV [left ventricular] ejection fraction
[EF] [of] 35% or less’’ as a separate moderate risk factor besides heart failure, whereas Singer et al. [10] lists ‘‘moderately or severely impaired
left ventricular systolic function and/or heart failure.’’ Impaired LVEF was unavailable in the data unless the resident had a diagnosis of
congestive heart failure
d AFFIRM study hazard ratios for covariates associated with major bleeding (with adjustment): age, 1.05 per year; aspirin use, 2.01; hepatic or
renal disease, 1.93; warfarin use, 1.78; diabetes, 1.44; congestive heart failure, 1.43; first episode of atrial fibrillation, 1.30
e See ‘‘Age C65 years’’ in ‘‘Other bleeding risk factors’’ category for older age as a bleeding risk factor. The AFFIRM study reported that
bleeding risk increased with age when age is expressed as a continuous variable. Age categories were not evaluated. The average age of study
participants experiencing a major bleeding episode was 72.3 years
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been published. Bleeding risk factors were identified from
the Atrial Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM) study [22] and from other studies
[23, 24]. Bleeding risk factors (listed in Table 1) were
tallied by count and assigned to one of four levels: 0–1, 2, 3
and 4?.
Available ADL measures were comparable between
NNHS and AnalytiCare databases, because these were
derived from the same source: the MDS 2.0. The method of
Carpenter et al. [25] was used to derive a single ADL
functioning score from seven physical function assessment
items. Logistic regression models were used to predict the
odds of being prescribed warfarin by including, for each
resident, only stroke-risk and bleeding-risk category
assignments (no other resident characteristics). NNHS-
provided sampling weights were applied to derive all
estimates from that database. Intercooled Stata version 8.0




After applying inclusion criteria, NNHS had 1,454 eligible
residents with AFib (Table 2), representing (after applying
sampling weights) an LTC population of 162,061 having
AFib in the year 2004 (55,061 warfarin users and 107,000
non-users). The AnalytiCare database had 3,757 eligible
residents with AFib.
Table 3 shows characteristics of residents with AFib. In
the NNHS, the median age was 85 years; 70 % were
female. In AnalytiCare, median age was 83 years; 63 %
were female. In the NNHS, age and sex distributions were
similar between residents having AFib who were receiving
warfarin therapy and those who were not. In AnalytiCare, a
smaller proportion of residents over 85 years of age (37 %)
were receiving warfarin compared with those not receiving
warfarin (50 %; p \ 0.001 for age distribution); the sex
distribution was similar between these groups.
In both the NNHS and AnalytiCare, residents receiving
warfarin had a more favourable distribution of ADL
functioning (less physical dependence; p = 0.050 and
p \ 0.001, respectively, Table 3) compared with non-
users. In both databases, warfarin users had a higher mean
CHADS2 score (indicating greater stroke risk) than non-
users, although group differences in scores were small: 0.2
(NNHS; p = 0.001) and 0.1 (AnalytiCare; p = 0.003)
points. Except for deep vein thrombosis, rates of common
chronic conditions (excluding stroke or bleeding risk fac-
tors) were generally similar among warfarin users and non-
users in both databases (Table 3).
3.2 Individual Stroke and Bleeding Risk Factors
Table 1 compares the proportion of residents having each
of the individual stroke risk factors. The distribution of
high risk factors was similar among warfarin users and
non-users in AnalytiCare. In the NNHS, warfarin users had
higher rates of previous stroke (p = 0.001) and mitral
stenosis (p = 0.046) than non-users (previous stroke is also
Table 2 Application of inclusion criteria to obtain eligible residents for analysis




NNHS All residents who were included in the NNHS database n/a 13,507 [1,492,207]
Had an open-ended entry for AFib (ICD-9-CM diagnostic code 427.3X) in any
of the 15 available current diagnosis fields on the resident questionnaire
12,053 [1,330,146] 1,454 [162,061]
Eligible residents retained for analysis n/a 1,454 [162,061]
AnalytiCare All residents who had complete pharmacy data, C2 MDS assessments, and an
entry for AFib (ICD-9-CM diagnostic code 427.3X) in any MDS assessment
completed during the study period 1 January 2007–30 June 2009
n/a 6,391
Had an MDS assessment at least 1 year prior to the end of the study period 1,830 4,561
Had a diagnosis for AFib within 1 year of the earliest MDS assessment 343 4,218
Had a complete admission or annual assessment within 1 year of the earliest
MDS assessment
456 3,762
Was C18 years of age on 1 January 2007 and his/her sex was known 5 3,757
Eligible residents retained for analysis n/a 3,757
AFib atrial fibrillation, ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification, MDS Minimum Data Set,
n/a not applicable, NNHS National Nursing Home Survey
a NNHS-provided sampling weights were applied to derive population estimates
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listed in combination with transient ischaemic attack [TIA]
as a bleeding risk factor). For moderate stroke risk factors,
warfarin users and non-users in the NNHS had similar
distributions. However, in AnalytiCare, compared with
non-users, a lower proportion of warfarin users were aged
C75 years (p = 0.003), a larger proportion had diabetes
mellitus (p = 0.026), and a larger proportion had conges-
tive heart failure (CHF) (p \ 0.001) (diabetes mellitus and
CHF are also listed as bleeding risk factors). The distri-
bution of less validated or weak association factors was
similar between warfarin users and non-users between
databases, except for a higher proportion of residents in the
65–74 age group among warfarin users in AnalytiCare
(p = 0.002).
Table 1 also compares the proportion of residents hav-
ing each of the individual bleeding risk factors. In the
NNHS, a lower proportion of warfarin users (11 %) were
taking aspirin compared with non-warfarin users (48 %;
p \ 0.001). Similarly, in AnalytiCare, a lower proportion
of warfarin users (5 %) were taking aspirin compared with
















Age, year (\75 year referent) 11 12 0.615 20 17 \0.001
75–84 33 30 43 33
C85 57 58 37 50
Female 72 69 0.344 64 63 0.273
Race/ethnicity (White referent) 92 89 0.010 85 81 0.006
Black 4 7 8 10
Hispanic 3 1 6 7
Other 1 3 2 2
Physical functioning
ADL assessment from MDS using Carpenter scorec [25]
(independent, score \14 referent)
41 35 0.050 29 26 \0.001
Moderate (score C14 and \21) 33 33 55 51
Dependent (score C21) 26 32 16 22
Hospice/\6 months to live 1 4 0.005 1 3 \0.001
CHADS2 stroke risk index [6]
0 1 3 0.021 1 1 0.044
1 17 21 10 13
2 31 35 28 31
3 30 26 29 28
4 13 11 19 16
5 6 4 9 8
6 2 1 3 3
Mean (±SE) CHADS2 score 2.6 (0.07) 2.4 (0.04) 0.001 2.9 (0.03) 2.8 (0.03) 0.003
Comorbid conditions not elsewhere listed as a stroke or bleeding risk factor
Deep vein thrombosis 6 2 0.004 7 4 \0.001
Peripheral vascular disease 11 12 0.671 19 18 0.200
Depression 35 33 0.374 47 49 0.148
Emphysema/COPD 18 20 0.390 30 29 0.288
Cancer 6 9 0.053 10 9 0.385
ADL activities of daily living, CHADS2 Cardiac Failure, Hypertension, Age, Diabetes, [and] Stroke [Doubled], COPD chronic obstructive
pulmonary disease, MDS Minimum Data Set, NNHS National Nursing Home Survey, SE standard error
a Sampling weights were applied to NNHS data to determine population estimates and frequencies
b Chi-square test (proportions), t test (mean)
c Score range 0–28, where a higher score indicates greater physical functioning dependence (i.e. worsened ADL performance)
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non-warfarin users (8 %; p \ 0.001), although under-
reporting of over-the-counter aspirin use is noted as a
limitation of the latter database. In both databases, com-
pared with non-users, a significantly smaller proportion of
warfarin users had dementia or cognitive impairment
(p = 0.042 NNHS; p \ 0.001 AnalytiCare) or were cur-
rently using antiplatelet therapy (p \ 0.001 for both dat-
abases). In AnalytiCare only, a smaller percentage of
warfarin users were anaemic when compared with non-
users (p = 0.011).
3.3 Rate of Warfarin Use by Bleeding and Stroke
Risk Category
Table 4 shows the rate of warfarin use for each combination
of stroke risk and bleeding risk category for residents in each
database. In the NNHS, 34 % of all residents with AFib were
receiving warfarin (95 % CI 31.1–36.8). Thirty-six per cent
of all AFib residents with high stroke risk (2? moderate or
1? high risk factors) were receiving warfarin. Findings were
similar in the AnalytiCare database: a minority (45 % of all
residents with AFib) were currently receiving warfarin (95 %
CI 43.0–46.1) and 45 % of residents with high stroke risk
were receiving warfarin. In both databases, warfarin use
generally increased with higher stroke risk among residents
in the same bleeding risk category.
3.4 Distribution of Resident Counts by Stroke
and Bleeding Risk
Figure 1 shows the distribution of residents in each cate-
gory of stroke and bleeding risk, without regard to warfarin
use. Findings were similar among both databases. A
majority of all residents with AFib in the NNHS database
(78 %) and in the AnalytiCare database (87 %) were
classified as having high stroke risk. In both databases,
approximately three out of every four of these high-stroke-
risk residents had at least three or more bleeding risk
factors.
3.5 Modelling Warfarin Use from Stroke and Bleeding
Risk
Figure 2 shows, from the single logistic regression model
within each database, the odds of a resident being pre-
scribed warfarin according to stroke and bleeding risk
category.
In the NNHS, compared with the ‘none or 1? weak’
stroke risk factor(s) and ‘0–1’ bleeding risk factors’ ref-
erent categories (odds ratio [OR] = 1), the odds of
receiving warfarin consistently increased with greater
stroke risk: 1 moderate, OR = 1.93 (p = 0.118, 95 % CI
0.85–4.38); 2? moderate, OR = 3.19 (p = 0.005, 95 % CI
1.42–7.17); and 1? high, OR = 8.18 (p B 0.001, 95 % CI
3.49–19.16). The odds of receiving warfarin consistently
decreased with greater bleeding risk: 2 risk factors,
OR = 0.83 (p = 0.366, 95 % CI 0.56–1.24); 3 risk factors,
OR = 0.47 (p B 0.001, 95 % CI 0.31–0.70); and 4? risk
factors, OR = 0.17 (p B 0.001, 95 % CI 0.11–0.26).
A similar, consistent trend was observed for Analyti-
Care, although only two risk factors were significant. For
stroke risk: 1 moderate, OR = 0.99 (p = 0.973, 95 % CI
0.55–1.78); 2? moderate, OR = 1.55 (p = 0.138, 95 % CI
0.87–2.75); and 1? high, OR = 1.79 (p = 0.052, 95 % CI
\1.0–3.23). For bleeding risk: 2 risk factors, OR = 0.91
(p = 0.479, 95 % CI 0.69–1.19); 3 risk factors, OR = 0.68
(p = 0.004, 95 % CI 0.52–0.88); and 4? risk factors,
OR = 0.54 (p B 0.001, 95 % CI 0.41–0.70).
Table 4 Rates of warfarin use by stroke and bleeding risk category




1 moderate 2? moderate 1? high 2? moderate or
1? high (combined)
NNHS 0–1 20 43 55 80 56 45
2 11 41 51 78 54 50
3 0 31 37 60 42 40
4? 0a 7 17 32 21 19
All bleeding risks 17 30 32 46 36 34
AnalytiCare 0–1 41 44 56 55 56 49
2 43 47 50 59 52 51
3 50a 37 44 53 46 45
4? 0a 14 42 41 42 41
All bleeding risks 42 39 45 46 45 45
NNHS National Nursing Home Survey
a Small counts (sample, n \ 10); age C75 years was considered a bleeding risk
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4 Discussion
Our study showed that of every ten LTC residents with
AFib, eight (NNHS) and nine (AnalytiCare) were at a high
risk for stroke (i.e. had 2? moderate or 1? high stroke risk
factors). A majority of residents (six and seven of every
ten, respectively) had high stroke risk combined with
3? bleeding risk factors. This is not unexpected, since
several key risk factors listed are common to both stroke
and bleeding risk assessments (e.g. previous stroke or TIA,
CHF and diabetes mellitus). An earlier study of Canadian
LTC residents with AFib by Lau et al. [16], using ACCP
guidelines [10] to define risk, found that nearly 97 % had
high stroke risk. Thus our study affirms Lau et al.’s [16]
finding of a high and continuing level of need for consid-
eration for stroke risk reduction in the LTC population.
4.1 Rates of Warfarin Use
Findings from the present study also revealed that fewer
than half of all residents with AFib (including fewer than
half of all residents with high stroke risk) were receiving
warfarin prophylaxis. Although warfarin usage increased
from 34 % in the 2004 NNHS database to 45 % in the
600 20 40 80 100
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Fig. 1 Percentage of all
residents with atrial fibrillation
by stroke and bleeding risk
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2007–2009 AnalytiCare database, overall usage of warfarin
in residents with AFib remains low. These findings are
generally consistent with five earlier regional LTC studies
that evaluated the use of warfarin in AFib among US and
Canadian nursing home facilities prior to 2004 [13–17] and
one that examined the same NNHS database used in the
current study [18]. Abdel-Latif et al. [13] found that 46 %
of residents with AFib were using warfarin, and Gurwitz
et al. [14] found that 32 % were. Three of these studies also
evaluated the use of warfarin when patients were stratified
by stroke and bleeding risk. Lau et al. [16] found that
warfarin was prescribed for 57 % of AFib residents.
Among high-stroke-risk/low-bleeding-risk candidates, the
warfarin prescribing rate remained similar at 60 %.
Lackner and Battis [15] found that only 17 % of patients
with non-valvular AFib received warfarin, whereas among
residents with 1? additional risk factor for stroke and no
contraindication, 20 % received warfarin. McCormick et al.
[17] reported that although 42 % of residents with AFib
received warfarin, only 53 % of ‘ideal’ candidates for
warfarin therapy (i.e. no bleeding risk factors) received oral
anticoagulant prophylaxis. Ghaswalla et al. [18] found
usage of warfarin among only 30 % of appropriate candi-
dates in the NNHS database (residents who had an indi-
cation for warfarin and no contraindications against its
use); these authors further found that of the remaining 70 %
not receiving warfarin, only 23 % had been placed on
antiplatelet therapy (aspirin or clopidogrel). Findings
regarding low anticoagulant usage have also been noted
within non-LTC community settings. In a recent systematic
review, Ogilvie et al. [26] found suboptimal (\70 %)
anticoagulant usage in seven of nine studies of patients
who had both AFib and a CHADS2 score of C2.
4.2 Modelling of Stroke and Bleeding Risk
Findings from our logistic regression analysis showed that
stroke and bleeding risk components, when evaluated
together within the same resident with AFib, have a con-
sistent, directional relationship with warfarin use.
*Stroke risks are compared with none or 1+ weak stroke risk factor(s) and 
bleeding risks are compared with 0–1 bleeding risk factors
95 % confidence interval
AnalytiCare database
1010.1
4+ bleeding risk factors
3 bleeding risk factors
2 bleeding risk factors
High stroke risk (1+ high)
High stroke risk (2+ moderate)
Moderate stroke risk (1 moderate)
Odds ratio
1010.1
4+ bleeding risk factors
3 bleeding risk factors
2 bleeding risk factors
High stroke risk (1+ high)
High stroke risk (2+ moderate)
Moderate stroke risk (1 moderate)
National Nursing Home Survey databaseFig. 2 Odds of being
prescribed warfarin according
to stroke and bleeding risk
category
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Increased stroke risk and reduced bleeding risk are asso-
ciated with greater odds of receiving warfarin; the converse
also applies. This finding contrasts with Lau et al.’s [16]
earlier finding of discordance between antithrombotic use
and relative risk of bleeding but agrees with McCormick
et al.’s [17] finding of lower warfarin use among residents
with 2? bleeding risk factors. An unexpected finding in the
NNHS data is that residents with high stroke risk classified
as having 1? high stroke risk factor(s) usually had greater
odds of receiving warfarin than those with high stroke risk
classified as 2? moderate risk factors, despite the risk
equivalence of these categories.
Despite consistency in the stroke–bleeding risk rela-
tionship with warfarin use, we found evidence of an upper
limit or plateau in usage—a finding also noted in earlier
studies [15–17] and in a recent systematic review that
concluded that bleeding risk alone may not explain low
rates of warfarin use for AFib in LTC [27]. Except for the
small number of residents with a combination of 0–2
bleeding risk factors and 1? high stroke risk factors in the
NNHS database (who had a 78–80 % rate of warfarin use),
warfarin use did not otherwise exceed 60 % among resi-
dents with AFib in either database, and was typically
lower, regardless of which category of combined stroke
and bleeding risk was evaluated (Table 4).
4.3 Potential Reasons for Limits in Warfarin Use
Addressing similar limits to warfarin use as observed
among residents with higher stroke risk, McCormick et al.
[17] and Lau et al. [16] cited the potential unavailability of
patient preferences, care directives, or other data from the
medical records they examined as possible explanations for
the low rate of warfarin use in AFib. Additional reasons for
warfarin underuse included difficulty in monitoring anti-
coagulation therapy [17], concerns about the risk of
bleeding complications that outweigh concerns about the
risk of stroke [17], knowledge deficits regarding risk fac-
tors for stroke and the effectiveness of warfarin for stroke
prevention in older patients with AFib [16, 17], under-
recognition of AFib [16], and past experiences with anti-
thrombotics [16].
Two studies of physicians who responded to hypothet-
ical AFib case studies in LTC settings showed that they
were most concerned about the risk of falls [28, 29],
dementia [28], limited life expectancy [28], a history of
gastrointestinal (GI) bleeding and non-CNS bleeding [29],
and a history of ischaemic stroke [29]. We found no effect
on warfarin use from a history of falling (Table 1), but our
findings support many of these physician-reported factors,
including a strong effect of dementia or cognitive impair-
ment (both databases), effects due to limited life expec-
tancy (both databases), and GI bleeding (AnalytiCare).
Both databases revealed that LTC residents receiving
warfarin appeared to have better physical functioning (i.e.
lower ADL dependence). Although it has not been reported
to be a bleeding risk factor, poor physical functioning can
be added to the list of factors that might negatively influ-
ence the use of warfarin in the LTC facility.
4.4 Limitations
A primary source of data in both the NNHS and Analyti-
Care databases was the MDS 2.0. Although the validity and
reliability of the MDS can vary by a given indicator [30],
the MDS 2.0 has been reported to generally have moderate,
or moderate to high, validity and reliability [31]. In both
study databases, current medication use was evaluated by
temporal proximity to the AFib diagnosis (under-reporting
of aspirin use in the AnalytiCare database was described
above). Other non-AFib indications for warfarin use, such
as post-myocardial infarction secondary prevention, were
possible. No distinction was made by type of AFib (e.g.
valvular/non-valvular, paroxysmal/persistent), although
warfarin is used for stroke prophylaxis among AFib variants
[9]. Specific stroke and bleeding risk factors identified in
consensus guidelines have not been validated against stroke
and bleeding outcomes in the LTC setting. Our model tested
an amalgam of summary measures of stroke and bleeding
risk taken from AFib guidelines and medical literature.
Other risk factors considered in new models may have been
relevant but were not included (e.g. bleeding risk factors:
some items listed in HAS-BLED [20] [such as hypertension
and poor International Normalised Ratio (INR) control] and
some items listed in REACH [21] [e.g. smoking and
hypercholesterolaemia]). As noted, several factors in our
list are counted as both stroke and bleeding risks, and this
remains a limitation even among newer models such as
HAS-BLED and REACH. Although a difficult issue to
reconcile, this degree of overlap limits the ability of models
to discriminate among summary stroke and bleeding cate-
gories when these are considered together.
5 Conclusion
Although our two study databases differed in design, scope
and time period of data collection, findings from the
analysis of each appear similar. High-stroke-risk patients,
who are known to have the greatest net clinical benefit
from warfarin use [5, 29], comprised approximately 80 %
or more of AFib residents in our two databases. Consistent
with our findings and those from earlier research [15, 16,
21], warfarin use continues to appear low among residents
with AFib in the LTC setting. Further research is needed to
evaluate the degree to which this low usage rate represents
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appropriate balancing of stroke and bleeding risk or other
concerns in these unique patients, or whether this repre-
sents a potentially large lost clinical benefit from otherwise
preventable stroke.
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